{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-24-000083","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.811167+00:00","generated_at":"2026-05-31T10:08:32.840317+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"AEON Biopharma plans biosimilar development of ABP-450 targeting BOTOX; FDA meeting set for Q3 2024","bullets":["ABP-450 will be developed as a biosimilar using BOTOX as reference product under 351(k) pathway.","Biosimilar initial advisory meeting with FDA scheduled for Q3 2024.","Planned Phase 3 cervical dystonia study of ~400 patients to compare ABP-450 to BOTOX.","No specific financial results for Q2 2024 were disclosed in the press release.","Company notes development is subject to securing funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-24-000083","json":"https://secwatch.observer/filing/0001837607-24-000083.json","markdown":"https://secwatch.observer/filing/0001837607-24-000083.md","text":"https://secwatch.observer/filing/0001837607-24-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000083/0001837607-24-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000083/aeon-20240812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:08:32.840317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}